NEW YORK--(BUSINESS WIRE)--Dec. 1, 2005--Callisto Pharmaceuticals, Inc. (AMEX:KAL)(FWB:CA4), a developer of new drug treatments in the battle against cancer and other serious health threats, today announced that an abstract describing research into the effect of its new anti-cancer drug Atiprimod on leukemia cancer cells has been accepted for poster presentation at the annual meeting of the American Society of Hematology (ASH), December 10 -- 13, 2005, in Atlanta, Georgia.
